Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00456053 · ClinicalTrials.gov registry record · Phase 2
A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin
A Phase 2 study, sponsored by Kyntra Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 145
- Enrollment target
NCT00456053 is a Phase 2 study that has completed, run by Kyntra Bio. The registered enrollment target is 145 participants.
The verdict
NCT00456053, a Phase 2 study, has completed, sponsored by Kyntra Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 145 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and efficacy of FG-2216 in the treatment of patients with renal anemia who are not receiving erythropoietin and who are not on dialysis.
Interventions
- DRUG FG2216
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00456053
The ClinicalTrials.gov registry entry for NCT00456053 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyntra Bio, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FG2216 is the first listed.
NCT00456053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00456053 about?
NCT00456053 is a clinical study titled "A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin". The purpose of this study is to test the safety and efficacy of FG-2216 in the treatment of patients with renal anemia who are not receiving erythropoietin and who are not on dialysis.
What is the current status of trial NCT00456053?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 145 participants. The study started on 2005-12. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00456053?
The interventions under investigation include: FG2216 (DRUG).
Who is sponsoring clinical trial NCT00456053?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.